[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100445417":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":44,"locations":49,"responsibleParty":67,"collaborators":70,"id":73,"slug":29,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":29,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":29,"enrollmentInfo":81,"targetDuration":29,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":51,"whyStopped":29,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Clinicians Interviews","EXPERIMENTAL","Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.",[13],"Other: Interview with Clinicians",{"label":15,"type":10,"description":16,"interventionNames":17},"Lymphoma Survivors Field Test","A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.",[18],"Other: Field Test of UPLYFT with Lymphoma Survivors",{"label":20,"type":10,"description":21,"interventionNames":22},"UPLYFT Pilot","Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.\n\nParticipants will be randomized 1:1 to either UPLYFT or usual care.",[23],"Behavioral: Pilot of UPLYFT with Lymphoma Survivors",[25,30,34],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Interview with Clinicians","One time, qualitative interview of clinicians for feedback on UPLYFT intervention",[9],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Field Test of UPLYFT with Lymphoma Survivors","6 session of UPLYFT intervention with Lymphoma Survivors for feedback",[15],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":29},"BEHAVIORAL","Pilot of UPLYFT with Lymphoma Survivors","6 session of UPLYFT intervention with Lymphoma Survivors",[20],[40],{"name":41,"affiliation":42,"role":43},"Oreofe O Odejide, MD, PhD","Oreofe_Odejide@dfci.harvard.edu","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":29,"email":42},"Oreofe O Odejide, MD, MPH","CONTACT","(617) 632-6864",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-71.05977,42.35843,{"lat":61,"lon":60},[64,66],{"name":46,"role":47,"phone":65,"phoneExt":29,"email":42},"617-632-6864",{"name":46,"role":43,"phone":29,"phoneExt":29,"email":29},{"type":43,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Oreofe Odejide, MD","Principal Investigator",[71],{"name":72,"class":6},"American Society of Hematology","100445417",false,"NCT05080166","UPLYFT For Lymphoma Survivors","An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors","Inclusion Criteria:\n\nLymphoma Survivors Phase 1 and 2:\n\n* Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)\n* Age ≥ 18 years\n* Interval of 3 months to 24 months from completion of first-line treatment\n* In complete remission after first line of treatment\n* Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \\[FCRI-SS).\n* Access to computer (for videoconferencing)\n\nLymphoma clinicians and mental health clinicians Phase 1:\n\n* Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.\n* Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians\n\nExclusion Criteria:\n\nLymphoma Survivors Phase 1:\n\n* Age \\\u003C 18 years\n* Concurrent other malignancy\n* Patients with uncontrolled\u002Funtreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).\n\nLymphoma Survivors Phase 2:\n\n* Age \\\u003C 18 years\n* Concurrent other malignancy\n* Patients with uncontrolled\u002Funtreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).\n\n  * Our study will exclude members of the following special populations:\n\n    * Adults unable to consent\n    * Individuals who are not yet adults (infants, children, teenagers)\n    * Pregnant women\n    * Prisoners","ALL","18 Years",{"count":82,"type":83},74,"ESTIMATED","INTERVENTIONAL",[86],"NA","The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.",[89,90],"Lymphoma","Survivorship",[89,90],"2026-02-20",{"date":94,"type":95},"2026-02-24","ACTUAL",{"date":97,"type":95},"2022-02-08",{"date":99,"type":83},"2026-08-31",{"name":5,"class":6},1]